Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.
By Melanie Senior
It has been clear throughout 2005 that M&A offers many private US biotechs a better deal than IPOs. (See "Stepping Out, Not Up?" START-UP, May 2005 Also see "Stepping...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
